A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed

A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer is a phase 2, randomised interventional study registered as NCT06525350 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., with a registry enrolment figure of 256 participants, started 2024-07 and due to reach its primary completion in 2026-12-25. Interventions recorded: Glumetinib tablets; HB1801 (docetaxel, albumin-bound）; Docetaxel. Conditions listed: Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression. Primary outcome: Dose-limiting toxicity(DLT) occurrence and incidence; Recommended phase 2 dose(RP2D) of the combination therapy; Adverse events (AE) and serious adverse events (SAE) occurrence and incidence. Lung eligibility wording from the registry: "Unresectable locally advanced or metastatic non-small cell lung cancer (IIIB, IIIC, or IV according to the 8th edition TNM staging standards of IASLC) confirmed by histology or cytology;". No results are recorded here; the registry entry is the source.